Aging and Dementia: AAN 2017
Studies examined the impact of blood pressure trajectories on dementia risk and explored the relationship between sleep apnea and Aβ accumulations.
Epilepsy Highlights: AAN 2017
Highlights: imaging the temporal dynamics & cellular architecture of seizures in Dravet syndrome, & reducing risk of spontaneous fetal loss.
Chronic Traumatic Encephalopathy: Potential Biomarker
Blood protein analysis of plasma total tau has diagnostic use in Alzheimer disease. Could the same hold true for CTE?
Acute Stroke Treatment and Outcomes: AAN 2017
The effect of blood pressure on IAT safety and benefit and pediatric stroke outcomes based on treatment were some of the studies presented at AAN.
Best of MS: AAN 2017
The four top-scoring MS abstracts submitted for AAN 2017 included 6-year outcomes with alemtuzumab treatment and pediatric MS environmental risk factors.
Migraine Prevention: Promising New Drug
Peter Goadsby, MD discusses the efficacy, safety, & tolerability of the CGRP inhibitor erenumab in a phase III trial of participants with episodic migraine.
New SUDEP Guidelines Clarify Risk Factors
The new SUDEP guidelines, co-developed by the AAN & AES and presented this week at the AAN Annual Meeting, provide clarity to health professionals.
Parkinson Disease: Genetic Findings
Research at AAN 2017 highlights research of genes that may help predict the likelihood of developing Parkinson disease and progression of the disease.
Lennox-Gastaut Syndrome: Cannabidiol Treatment
What was the impact of add-on cannabidiol treatment in patients aged 2-55 years experiencing drop seizures?
AAN 2017: Must-See Sessions
You won’t want to miss these new features and sessions at this year’s American Academy of Neurology Annual Meeting, April 22-28, in Boston, MA.